Company news

Pulse Biosciences, Inc (NASDAQ:PLSE) news

Pulse Biosciences, Inc news releases on 6ix. Latest, Sep 15, 2026: Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating…

Pulse Biosciences, Inc (NASDAQ:PLSE) news

Press releases & updates

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

Pulse Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Pulse Biosciences to Host Analyst Event on April 25, 2026

Pulse Biosciences Strengthens Executive Leadership Team

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025